文献速递前列腺癌

前列腺癌放疗后粪失禁的系统综述

Fecal incontinence after prostate cancer irradiation: a systematic literature review.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-02-02

报告发生率1%–12%,多表现为排气或稀便漏出,需护垫的重度形式少见;肛管平均剂量建议低于37 Gy,但缺乏标准化评估工具。

要点

  • 前列腺癌放疗后粪失禁发生率1%–12%,多表现为排气或稀便漏出。
  • 肛管平均剂量建议低于37 Gy,直肠高剂量亦贡献粪失禁风险。
  • 缺乏统一评分系统,建议开发经验证的量表以规范评估。

核心结论

  • 前列腺癌放疗后粪失禁因缺乏标准化评估可能被低估,开发通用评分系统是优先事项。

主要发现

  • 粪失禁源于肛直肠系统功能、形态和神经改变,报告发生率1%–12%。
  • 多数表现为排气或稀便漏出,需护垫的重度形式不常见。
  • 危险因素包括高龄、既往腹部手术、血管合并症、慢性炎症性肠病、痔疮及放疗期间便急。
  • 剂量学分析显示肛管低中剂量与直肠高剂量对粪失禁贡献不同。

关键数值与推荐

  • 基于当前证据,肛管平均剂量应保持在37 Gy以下。
  • MRI勾画、直肠内球囊及直肠周围水凝胶间隔物等预防策略显示前景。

临床怎么用

  • 管理需多学科协作,包括饮食措施、药物、盆底治疗、神经调节,严重者可行转流手术。

局限性

  • 定义和评估工具异质性大,无普遍适用的标准化评分系统。
  • 肛管和直肠的精确剂量约束仍需进一步研究确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

GOAL: Fecal incontinence (FI) is an underrecognized but clinically significant late gastrointestinal toxicity following radiotherapy (RT) for prostate cancer. This systematic review aimed to synthesize current knowledge on the definition and pathophysiology of post-radiation anal continence, as well as prevention strategies, technical considerations, and therapeutic approaches. METHOD: A systematic literature search was conducted according to PRISMA guidelines using the keywords: "Fecal incontinence," "Radiation therapy," and "Prostatic neoplasms." Eligible studies included randomized phase III trials and prospective or retrospective series reporting on FI after definitive or adjuvant/salvage prostate RT. Fifty-four articles were included in the final analysis. RESULTS: FI after prostate RT results from functional, morphological, and neurogenic alterations of the anorectal system. Reported incidence ranges from 1 to 12%, most often presenting as flatulence or liquid stool leakage, while severe forms requiring pads are uncommon. Variability is largely explained by heterogeneity in definitions and assessment tools, as no standardized scoring system is universally applied. Risk factors include advanced age, prior abdominal surgery, vascular comorbidities, chronic inflammatory bowel disease, hemorrhoids, and rectal urgency during RT. Dosimetric analyses indicate that low-to-intermediate doses to the anal canal and high doses to the rectum contribute differentially to FI. Based on current evidence, the mean dose to the anal canal should be kept below 37 Gy, though further studies are needed to define precise constraints for both structures. Preventive strategies such as MRI-based contouring and endorectal balloon placement, perirectal hydrogel spacers placement show promise. Management is multidisciplinary, including dietary measures, medications, pelvic floor therapy, neuromodulation, and, in severe cases, diversion procedures. CONCLUSION: FI after prostate RT is likely underestimated due to the absence of a standardized assessment. Developing a validated, universally applicable scoring system is a priority to improve evaluation, enable cross-study comparisons, refine preventive measures, and guide therapeutic strategies.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Benizri D, Duchalais-Dassonneville E, Gautier M, et al. Fecal incontinence after prostate cancer irradiation: a systematic literature review. Prostate Cancer Prostatic Dis. 2026. PMID: 41629638. doi:10.1038/s41391-026-01078-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。